InterMune Articles
New idiopathic pulmonary fibrosis treatment may open up valuable research opportunity, says GlobalData
17 April 2013
UK pharma group slams NICE for failing to recognize nature of discovery and development
7 December 2012
UK's NICE initially negative on InterMune's Esbriet for idiopathic pulmonary fibrosis
30 November 2012
French price regulator authorizes reimbursement of InterMune's Esbriet
12 September 2012
Esbriet offers additional benefit, says German G-BA
16 March 2012
Germany’s IQWIG negative on InterMune’s Esbriet
18 December 2011
Longer-term safety profile of InterMune’s Esbriet in IPF demonstrated; Call for greater awareness of PF
26 September 2011
InterMune’s IPF drug Esbriet sees first European launch, in Germany
13 September 2011
InterMune prepares for European launch of Esbriet after positive CHMP opinion with management appointments
20 December 2010
Showing 1-19 of 19 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
